I believe CPXX was trading near or below cash value, just before its Phase III results were announced. It went from $1.12 to over $30 in six weeks. Maybe the exception that proves the rule.
CPXX may be the exception to another (Feuerstein) rule: No micro-cap biotech can take an oncology drug successfully through pivotal trails.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.